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Chapter 4
Homology Models of Human
Adrenergic Receptors
The increased availability of high-resolution GPCR crystal structures has enabled
deeper investigation into homology modeling as a method for GPCR structure pre-
diction. Most homology models currently available were built based on bovine
rhodopsin, but low sequence identity between rhodopsin and most GPCR targets
of interest for drug development casts some doubt on the utility of these models.
The most recent structures for two adrenergic receptors offer the opportunity to
create high-quality homology models for the entire human adrenergic GPCR fam-
ily. Using the homology model approach combined with the BiHelix / CombiHelix
method for helix η rotation determination, structures for the eight remaining hu-
man adrenergic receptors were built. These structures were validated with ligand
docking studies, and the predicted binding sites offer some insight into subtype
selectivity in the family.
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4.1 Overview
Homology modeling, a method to model a GPCR structure based on an existing ex-
perimental structure, is widely used to determine overall structure, binding sites,
and subtype selectivity for GPCRs.12 For several years, only one GPCR, bovine
rhodopsin, was available for this kind of modeling.28–36 Most receptors of inter-
est are human GPCRs from other subtypes however, with low sequence identity
to bovine rhodopsin, complicating the process of building a homology model.65–67
The publication of several other GPCR crystal structures, including the human
β2 adrenergic receptor (β2),37–40 the closely related turkey β1 adrenergic receptor
(β1),41 and the human adenosine A2A receptor42 revealed close structural similarity
among the structures. This, as well as advances in ligand-steered homology mod-
eling,122 have inspired more confidence in the homology approach. Differences be-
tween individual receptors can arise, however, and they may be significant enough
to mislead conclusions during binding site studies or enquiry into the mechanism
of activation.123 For receptors with no closely related crystal data, ab initio structure
prediction methods such as those described in Chapter 2 are in continuing devel-
opment. For receptors with high similarity to existing crystal structures, however,
homology modeling remains a viable option for quick and accurate determination
of useful receptor data, especially for binding site studies. The recent publication
of two adrenergic GPCRs creates a unique opportunity for high-quality homology
modeling of the other adrenergic receptors.
Table 4.1 shows the sequence identity of the adrenergic receptors as well as
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Table 4.1: Identities between the human β2 and turkey β1 GPCRs with the other adrener-
gic receptors range from 24%–60% overall and up to 85% in the TM regions.
β2 Human β1 Turkey
All% TM% All% TM%
β1 41 68 60 85
β3 42 59 39 63
α1a 28 41 26 44
α1b 30 44 27 44
α1d 30 43 27 43
α2a 26 39 27 49
α2b 24 38 24 46
α2c 24 38 24 44
β2 – – 42 70
the identity of the TM regions used for the homology models. The nine adrener-
gic receptors are closely related to one another, even between different species, as
shown in the relationship between the turkey β1 receptor and the human β2 recep-
tor, which is closer by sequence identity than that between human β2 and human
β1. This close similarity implies that a homology approach for closely related re-
ceptors can be successful.
Along with relatively high sequence identity, the adrenergic receptors share
similar TM bundle arrangements. Table 4.2 shows the differences between avail-
able crystal structures relative to β2 with respect to η, θ, and φ angles. Although
there are large differences, the most consistently similar structures are the ones
with the highest sequence identity, such as β1 and β2 with 52% TM sequence iden-
tity with respect to β2. The next most similar structures are the two rhodopsin
examples, squid and bovine, with 27% identity. The adenosine receptor is less re-
lated to either of these two subtypes, with 25% identity with respect to β2 and
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Table 4.2: Rotation comparison of available GPCR crystal structures relative to human
adrenergic β2 (PDB: 2RH1), all expressed in degrees relative to β2. Structures are turkey
β1 (PDB: 2VT4), human adenosine A2a (PDB: 3EML), bovine rhodopsin (PDB: 1GZM), and
squid opsin (PDB: 2Z73).
η θ φ
β1 A2a rhod. opsin β1 A2a rhod. opsin β1 A2a rhod. opsin
tm1 -3.85 -7.44 -17.19 -11.92 -6.27 -6.28 -2.53 -5.87 -4.18 -24.00 -35.92 -30.12
tm2 4.97 15.80 -9.57 -16.64 -6.50 -8.86 -2.00 -0.89 -8.91 -8.85 -11.36 -6.56
tm3 -0.56 10.01 -11.2 16.35 -4.24 -6.58 -2.34 -1.85 4.17 -4.26 -23.97 -10.44
tm4 -4.32 6.18 1.72 17.98 2.18 4.86 -0.61 -0.54 -35.17 -7.45 -9.18 -3.00
tm5 -1.73 -3.32 -43.45 -37.16 0.85 0.37 -0.45 0.51 12.06 -13.01 -22.54 2.98
tm6 2.64 -3.98 -9.01 21.44 4.35 -9.19 -1.04 -3.81 -4.94 8.91 -1.07 -44.33
tm7 -4.14 -5.65 -7.02 -5.29 6.61 -2.60 6.65 2.96 -12.12 -10.22 -0.51 9.67
18% identity with respect to bovine rhodopsin. Even though the adenosine and
β2 receptors are from the same species, β1 (turkey) is more closely related, in both
amino acid sequence and helix orientation. The similarity in helix orientation is
even preserved despite different crystallization strategies.
This similarity indicates that homology modeling is a viable option for determi-
nation of all nine adrenergic GPCR structures. A simple procedure for homology
modeling can only provide a snapshot of the receptor, however, and as sequence
identities decrease through the family the possibility of that snapshot being inac-
curate increases. The methods developed for refinement of ab initio structure pre-
diction can not only provide insight into other possible conformations of a known
crystal structure and very closely related receptors, it can also predict the native
conformations of more distantly related structures. The rotation sampling meth-
ods also lend insight into which helices of each template structure are rigid or
flexible; which helices are locked into a conformation with strong conserved inter-
actions, and which are allowed to rotate or shift within the structure.
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In general, structures with higher identity between the target and template
GPCRs are expected to have better results with rapid, coarse homology model-
ing. The closely related β receptors should be modeled the most easily, while the
more distantly related α2 receptors may require more refinement. In this work,
both the β1 turkey and β2 human structures are tested as templates for the eight
human adrenergic receptors that lack X-ray crystal structures, and the resulting
models are validated with a novel docking protocol. Those structures with the
highest target-template identity enjoyed the most success, while those less related
will require further refinement before full validation.
4.2 Methods
General Methods: All calculations were carried out using the DREIDING force field92
with CHARMM2293 charges. Side chain placement was determined with SCREAM90
Unless otherwise noted, all simulations were performed in the gas phase with a di-
electric of 2.5.
4.2.1 Building the Homology Models
Each receptor was built based on both the β2 (2RH1) and β1 (2VT4) crystal struc-
tures, referred to as template structures. The β2 human structure was not built, as
it was used as a validation case for the homology method previously in the God-
dard group. Throughout the descriptions, structures are labeled according to their
name and their template, i.e., “α1a-β1” is the human α1a homology model built
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on the turkey β1 template.
Prediction of transmembrane regions: Preliminary TM helices were obtained via MAFFT95–97
alignment to the template receptor. These alignments were compared to the pre-
dicted helical regions from secondary structure prediction methods Porter,124 APSSP2,119
and PSIPred.125 The final helix used for the model included the shorter helix be-
tween the secondary structure predictions and the crystal alignment; in the cases
where no method predicted a helix but the crystal helix continued, the crystal he-
lix was truncated for the model. The chosen helix for β1 human, as an example, is
shown in Table 4.3. As a result, the TM lengths for a given receptor may be differ-
ent for different templates.
Simplified Helix Optimization: After creating the TM helices, we minimized the he-
lices in vacuum. This is a different procedure from the OptHelix method discussed
in Section 2.2. OptHelix, while offering a useful starting point for structure predic-
tions that rely on no other structural data other than a template for helix orienta-
tions, does not reproduce crystallographic helices with enough accuracy to deter-
mine crystallographic η rotations. For a homology model, helix shapes provided
from the crystal data are a suitable starting point for minimal receptor-specific op-
timization. Each receptor’s TM bundle was optimized by isolating each helix and
minimizing for 100 steps.
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Table 4.3: To determine the termini for homology helices, we considered results from sec-
ondary structure prediction methods Porter, APSSP2, and PsiPred. Starting with the crys-
tal helix from the chosen template, homology helices were truncated if all three secondary
structure predictions indicated a position would not be an αhelix. TM1 for β1 human and
α1a are shown here as an example. The template crystal helix is indicated in red, and the
final homology TM based on the combination of crystal alignment and secondary structure
prediction is indicated in red and bold.
β1 xtal GAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGSTQRL
β1 human SPEPLSQQWTAGMGLLMALIVLLIVAGNVLVIVAIAKTPRL
Porter cccccccHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHcccc
APSSP2 ccccccHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHcccc
PsiPred cccccccHHHHHHHHHHHHHHHHHHHHHHHEEEEEEEcccc
β1 homology SPEPLSQQWTAGMGLLMALIVLLIVAGNVLVIVAIAKTPRL
α1a PPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHL
Porter cccccHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHccccc
APSSP2 ccccccHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHccccc
PsiPred ccccccHHHHHHHHHHHHHHHHHHHHHHHHEEEEEEEcccc
α1a homology PPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHL
Helix Rotation Optimization: The BiHelix and CombiHelix methods determine the
low-energy helix η rotations, and are described in detail in Section 2.2. For each
receptor, the possible bundles are ranked by minimized energy.
4.2.2 Validation With Docking
A selection of structures was validated using docking and mutation studies. Each
receptor validation included a group of ligands with consistent experimental data,
with binding affinities sufficiently different (preferably 50-fold or more) to reliably
separate using force field energies.
Ligands were prepared by building in Maestro, conformation search with Macro-
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Model,126 and mulliken charge calculation with Jaguar (B3LYP with 6-31G** basis
set).127 For antagonists with multiple nitrogens, pKa values were calculated with
the pKa module in Jaguar.
Each receptor was validated using both β1 and β2 models, docked individually
with canonical subtype selective antagonists. The binding sites were predicted
using ScanBindSite.pl.80 The receptors were modified to replace bulky nonpolar
residues (tryptophan, tyrosine, phenylalanine, valine, isoleucine, and leucine) with
alanine, allowing polar interactions to dominate the binding site selection and ini-
tial ligand enrichment steps.
For all models, the binding sites were chosen using the endogenous agonist
epinephrine. In the adrenergic receptors, the conserved Asp3.32 serves as the key
anchor point for both agonists and antagonists bearing a protonated nitrogen. As
many antagonists function by blocking the agonist binding site as well as stabiliz-
ing the receptor’s inactive conformation, using the endogenous agonist for binding
site determination is both plausible from a theoretical standpoint and practical to
execute using current methods. ScanBindSite.pl uses a coarse implementation of
HierDock70 to place a ligand in a variety of small box regions over the entire empty
space of the receptor. These placements are ranked by energy and ligand buried
surface, and the regions corresponding to the best average energy at 80% buried
surface were selected for further analysis.
Once the binding site was selected, two diverse ligand conformations were
docked to the site using the recently developed DarwinDock, a Monte Carlo dock-
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ing procedure. The protein was converted back to the wild type with SCREAM,
then the ligands and charged residues were neutralized. This neutral complex was
minimized twice, first the binding site, then the entire complex. The final docked
poses were selected based on the energy from this final minimization.
In order to probe the binding sites of each receptor, subtype selective anatag-
onists were chosen and docked for each subtype. For the α1 subtype we chose
WB4101 and prazosin. WB4101 has been extensively studied128,129 as an α1 se-
lective antagonist and a particularly potent α blocker, while prasosin was one of
the first commercially developed α blocker. Yohimbine is a traditional α2 antag-
onist,130 and its rigid structure allowed for excellent docking with less sampling
than the other antagonists with more rotational degrees of freedom. In addition,
the endogenous agonists epinephrine and norepinephrine were docked to the α2
receptors to compare with results from ligand binding studies.131,132 For β1 and
β3, the β1 selective antagonist (−) RO 363 was docked. The residues implicated in
binding133 are conserved between β1 and β3, and a high quality docking pose can
illuminate the residues that give rise to this ligand’s selectivity.
4.3 Results and Discussion
While the GenSemble method was developed using 30◦ increments for sampling,
later studies in the Goddard group showed that BiHelix will resolve differences
in helix η rotation as fine as 10◦. This analysis exponentially increases the time
necessary for full 360◦ sampling, so the 30◦ scan remains the method of choice
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Table 4.4: The best TM bundles by minimized energy (kcal/mol) are shown for each
template-receptor pair. Bundles are represented as combinations of η rotations in degrees
relative to the template crystal structure. TMs 1, 2, and 3 are largely static, while TM4
shows some flexibility and a preference for a 15◦counterclockwise rotation from the crys-
tallographic orientation.
β2 Template β1 Template
H1 H2 H3 H4 H5 H6 H7 Energy H1 H2 H3 H4 H5 H6 H7 Energy
β1 0 0 0 345 0 0 0 -178.9 0 0 0 345 0 0 0 -202.1
β3 0 0 0 0 0 0 0 -183.1 0 0 0 345 0 0 0 -186.3
α1a 0 0 0 345 0 15 0 254.2 0 0 0 345 0 0 0 209.8
α1b 0 0 0 345 0 0 345 246.5 0 0 0 345 0 60 315 193.8
α1d 0 0 0 105 270 0 90 63.2 0 0 0 90 0 75 0 138.0
α2a 0 0 0 345 0 0 0 153.8 0 0 0 345 0 0 0 117.3
α2b 180 15 0 345 0 0 105 193.1 0 0 0 345 270 105 0 119.0
α2c 0 0 0 345 0 0 0 263.5 0 0 0 0 0 45 0 220.8
when scanning the entire range of possible rotations. Once a bundle has been
chosen, finer sampling in 15◦ increments within a 120◦ range is performed. The
final structures are chosen from this analysis, also based on minimized energy, and
the results are shown in Table 4.4. Most receptors in this study showed η rotations
analagous to the template crystal structure as the lowest in minimized energy after
building the full bundles. Those least related to the template strutures, α2b, α2c,
and α1d, had alternate rotations for TMs 4, 5, 6, and 7 in varying combinations
depending on the receptor and template. These alternatives were the starting point
for the finer rotational analysis, and the final structures are reported in Table 4.4
relative to the initial crystal-derived structure.
The final structures after the fine rotational analysis show a clear preference for
the 15◦ counterclockwise rotation of TM4. Conserved residues Arg4.41 and Arg4.40
are vertically positioned to interact with Asp3.49 and Asn2.40, respectively, if the η
rotation allows it. In the 0◦ position, both residues on TM4 may interact with their
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Figure 4.1: BiHelix/CombiHelix results indicate a counterclockwise rotation of TM4 is
favored over the crystallographic orientation for most receptor-template pairs. The inter-
actions responsible for this preference are illustrated below for the β1-β1 case.
partners in TMS 2 and 3, but only loosely. After the counterclockwise rotation the
interaction between TMs 3 and 4 is strengthened, the distance between the two
residues decreasing to 2.1 A˚ from the crystal orientation. This change is illustrated
in Figure 4.1. Optimizing this interaction has a greater effect on the overall protein
structure than compromising between the two, and this is reflected in the final
helix orientations for these models. This change is difficult to validate, as ligand
binding data for the adrenergic receptors confirms roles for all helices except TM4.
The discussion of helix motion in Chapter 3 indicates that TM4 may simply be
more dynamic than the other TM helices, and less important in ligand binding.
These charged residues in the helix termini may interact with loops or lipids
rather than other helices in the native protein. In Chapter 2, a modified BiHelix
method removed charged residues at the ends to avoid spurious interaction en-
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ergies. That case, however, involved helix shapes determined by OptHelix and
alignment to an average β2 crystal structure. In this homology model, the tem-
plate choice and helix shapes are matched, and expected to interact more like the
native protein. In previous studies, BiHelix/CombiHelix performed on the β1
crystal structure with truncated helices, the energy difference between the crys-
tallographic rotations and the next most stable structure was significantly smaller
than with full helices. This indicates that the intrahelical interactions in the helix
ends are important for TM bundle stabilization, and care should be taken when
deciding to ignore them. In the “blind” prediction case, it was appropriate to do
so; in this homology model case, it is not.
In ab initio structure prediction, total bundle energy governs the choice of he-
lix alignment template. As described in Chapter 2, several plausible templates are
built, then after an ensemble of TM bundles are built a final template decision is
made based on which template yields the lowest energy. In these homology mod-
els, the final bundle energies reflect a good match between the β1 template and
the β1 human and β3 structures. With TM sequence identities of 85% and 63%, re-
spectively, this indicates that sequence identity predicts the quality of a proposed
homology model. The next best structures, β1-β2 and β3-β2, have TM identities of
68% and 59% and overall identities of 41% and 42%. The overall sequence identity
implies the β3-β2 structure should be slightly better than the β1-β2 structure, and
this is seen in the relative energies. As the target sequence deviates from the tem-
plate sequence, and as the best rotations deviate from the initial crystallographic
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Figure 4.2: (−)RO-363 is a selective β1 antagonist. While residues implicated in β1 binding
are conserved in the β receptors, the predicted binding site should indicate which residues
are responsible for this ligand’s selectivity.
rotations, the energy of the best bundle increases, indicating a less favorable match
between template and target.
4.3.1 Validation with Docking and Mutation Studies
For swift validation of the adrenergic binding sites, we chose both agonists and
antagonists based on studies with mutation or SAR data available for subtype se-
lective ligands. The template crystal structures were crystallized with inverse ag-
onists, so the resulting structures are more likely to resemble the inactive forms of
the target receptors. The canonical “blocker” ligands should bind well to these in-
active forms. However, as mentioned in Chapter 2, use of a new docking protocol
meant to predict binding sites and poses without a knowledge-based judgement
call introduces uncertainty into the validation process. Many structures built for
this study could be validated with antagonist docking, but for those that could not
be, further efforts should concentrate first on refinement of the docking procedure
before revisiting the structure prediction.
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(−) RO-363 (Figure 4.2) is a β1 selective antagonist with recent, detailed muta-
tion data from studies carried out by Sugimoto, et al.133 Half of the molecule resem-
bles epinephrine, while the other half contains O-methyl groups that mimic some
α1 antagonists. The sites studied for human β1 antagonist binding are found at the
top of TMs 2 and 7, and single, double, and triple mutations are considered. Alone,
the mutation of Thr1172.63 or Phe3597.35 to alanine only have a small effect on bind-
ing, but combined they decrease antagonist affinity 25-fold. Leu1102.56 mutated to
alanine results in a seven-fold decrease in affinity, but that change is augmented
when paired with the Phe3597.35 mutation. The triple mutation also produces a 25-
fold decrease in affinity. Although RO-363 is a β1 selective antagonist, the residues
studied are conserved in β3. A good binding site for both receptors can indicate
what part of the binding site is important for this subtype selectivity.
The BiHelix / CombiHelix for both β1 human and β3 in both templates resulted
in TM bundles similar to the crystal templates. The only variation occurred in TM4,
and for β3-β2 all helices were found in the crystal orientations. Neither template-
target pair featured TM2 rotated such that the residues tested by Sugimoto, et al.
were accessible to the binding site, and both binding pockets were too deep in
the receptor to interact directly with Phe7.35. One pose, however, positioned one
side of the ligand where it might interact with Leu1102.56 with an alternate rota-
tion of TM2, and appropriate rotations do appear in the low-energy TM bundles
from CombiHelix. Both poses featured strong interactions in the binding pocket
with canonical adrenergic binding site residues, as shown in Figures 4.3 and 4.4.
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Figure 4.3: The best docked conformation of (−) RO-363 (in blue) to the β1-β2 homology
model was a folded conformation, with stabilizing interactions from the adrenergic agonist
pharmacophore as well as an internal hydrogen bond.
For both cases, the β2 template provided the best docked poses, possibly due to
all seven TM helices found in their crystallographic orientations. Although these
structures do not directly support some of the mutation data, the strong polar in-
teractions with canonical adrenergic binding site residues such as the TM5 serines
and TM3 aspartic acid imply these poses and structures are plausible forms of the
β1 and β3 human receptors.
Two sets of studies explored antagonist binding to α1 receptors: one focusing
primarily on WB4101 (Figure 4.5) and prazosin (Figure 4.6) binding to α1a,129 the
other performing extensive SAR on WB4101 and comparing the differences among
α1a, α1b, and a serotonin receptor.128 Waugh, et al. only studied α1a, but the
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Figure 4.4: The β3-β2 model binds a linear conformation of (−) RO-363, spanning the
entire TM core from the antagonist binding pocket near TMs 2 and 7 to the agonist binding
residues on TM5. The TM5 hydrogen bonding network is shown separately on the right.
Figure 4.5: WB4101 has been studied extensively as an α1 selective antagonist.
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Figure 4.6: Prazosin is a selective α1 antagonist, and is prescribed as an antihypertensive
drug.
residues mutated are conserved throughout the α1 subtype: Phe7.39 and Phe7.35,
both at the top of TM7. WB4101 is α1 selective, but binds more strongly to α1a
than to α1b or α1d. A good binding site for this ligand, then, can indicate which
nonconserved residues are important for subtype selectivity. This study found
that the upper phenylalanine, Phe7.35, is more important for prazosin binding than
for WB4104, and that the opposite holds for Phe7.39. The predicted binding sites
should reflect this difference.
The low-energy rotations for α1a-β1 are the most similar to the template rota-
tions of all the α1 homology results, with only the consistent TM4 anticlockwise
rotation deviating from the strictly analagous structure. This structure binds pra-
zosin well, and while the key Phe3087.35 residue does appear in the cavity anal-
ysis (Table 4.5) as a stabilizing residue, Phe3127.39 is the most important residue
in the best binding pose. By contrast, the WB4101 binding site does show sev-
eral residues interacting with the ligand: Asp1063.32 interacts with the protonated
amine (1.88 A˚); Tyr1845.36 binds to the O-methyl and ether groups simultaneously
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Figure 4.7: The α1a-β1 homology model docked WB4101 in a curled conformation sta-
bilized primarily through interactions with Asp1063.32, TM5, and TM7 phenylalanine
residues implicated in antagonist binding through mutation studies.
(2.90 and 2.67 A˚); and an internal hydrogen bond between the amine and the re-
maining O-methyl group stabilizes another polar interaction (2.38 A˚). These inter-
actions are illustrated in Figure 4.7. Both Phe3087.35 and Phe3127.39 are present in
the binding site and contribute to ligand binding, but as with prazosin the rela-
tive contributions are the reverse of what is expected. α1a-β2, which favors rota-
tion of TM6 15◦ clockwise in addition to the conserved TM4 rotation, could not be
docked with a plausible pose. Despite the higher sequence identity for α1a to the
β templates, this structure requires further refinement before the binding site can
be verified.
α1b favors a slight anticlockwise rotation of TM7, the conserved rotation of
TM4, and in the β1 template, an additional clockwise rotation of TM6. This α1b-
β1 structure shows the greatest deviation from the crystallographic orientations
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Table 4.5: While most of the key residues implicated by mutation studies appear in the
cavity analysis for α1a-β1 docked with WB-4101 and prazosin, they are not in the order of
priority suggested by the experiments. Further refinement of these docked structures may
yield more accurate results. Energies are reported in kcal/mol.
WB-4101 Prazosin
Residue VdW Coulomb Total Residue VdW Coulomb Total
Tyr184 -2.357 -1.109 -3.465 Phe312 -7.386 -1.411 -8.797
Met292 -2.039 0.025 -2.014 Asp106 -2.373 -1.299 -3.672
Phe308 -1.582 -0.062 -1.644 Trp285 -2.952 -0.437 -3.390
Phe288 -1.152 -0.178 -1.330 Lys309 -1.820 -0.836 -2.656
Ala103 -1.187 0.020 -1.167 Trp102 -2.053 -0.431 -2.484
Tyr316 -0.688 -0.290 -0.978 Cys110 -2.672 0.254 -2.418
Trp102 -0.597 -0.363 -0.960 Trp313 -0.837 -0.997 -1.834
Val185 -0.994 0.103 -0.890 Phe308 -1.049 -0.180 -1.229
Phe289 -1.101 0.266 -0.835 Val107 -0.908 -0.008 -0.916
Leu162 -0.852 0.027 -0.825 Tyr316 -1.646 0.745 -0.901
Phe193 -0.805 0.248 -0.557 Leu75 -1.076 0.195 -0.881
Trp285 0.234 -0.684 -0.450 Ala103 -0.433 -0.332 -0.765
Cys110 -1.315 0.868 -0.447 Ser83 -0.385 -0.232 -0.617
Glu181 -0.153 -0.213 -0.367 Phe281 -0.152 -0.386 -0.538
Thr111 -0.255 -0.054 -0.309 Ser319 -0.160 -0.341 -0.500
Ala189 -0.560 0.269 -0.291 Met292 -0.595 0.122 -0.473
Ser188 -0.358 0.151 -0.207 Phe193 -0.404 0.041 -0.363
Val79 -0.138 0.088 -0.050 Phe289 -0.595 0.290 -0.304
Ser192 -0.331 0.376 0.046 Val79 -0.794 0.513 -0.282
Phe312 -0.142 0.224 0.082 Leu80 -0.173 0.063 -0.110
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of the α1 receptors modeled here. Despite some docked structures that involved
loose interactions with residues implicated by homology in antagonist binding,
none of the favored docked structures of either prazosin or WB4101 supported the
mutation data for antagonist binding to the related α1a receptor. These structures
require more specialized refinement before they can be fully validated.
With comparable sequence identity to the other α1 receptors, α1d favors rota-
tions similarly divergent from the template rotations. Both templates showed TM4
rotations, but not the same magnitude as the other structures: α1d-β2 prefers a
105◦ clockwise rotation of TM4, and α1d-β1 favors a 90◦ clockwise rotation. This
may be due to a nonconserved glutamic acid at the intracellular end of TM4; the
effect of the charged residue at the ends of TMs can be dramatic, and this may
have contributed to the final η residue determination. This may be tested by mu-
tating these charged residues in the TM caps to alanine and repeating the BiHelix
analysis. The distinction between alanization in this case but not for the TM4 in-
teractions described above is that this case concerns a non-conserved residue. A
highly conserved residue is likely to mediate a significant interaction, while it is
more possible in this case that the residue is creating noise.
Even with this shift in helix η rotations, it was possible to obtain plausible
docked structures for WB4101 and prazosin for the structure built on the β2 tem-
plate. The WB4101 binding site is shifted towards the TM1-2-7 pocket, with Ser1532.61
forming a hydrogen bond with one of the dioxane oxygens, the larger phenyl
group with O-methyl substituents buried deep in the binding pocket, and Phe3847.35
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Table 4.6: The top ten residues in the cavity analysis for α1d-β2 include the key residues
implicated in mutation studies, Phe3847.35 and Phe3887.39 in the correct order of impor-
tance for both WB-4101 and prazosin. Energies are reported in kcal/mol.
WB-4101 Prazosin
Residue VdW Coulomb Total Residue VdW Coulomb Total
Phe388 -5.125 -0.983 -6.108 Glu157 4.205 -4.366 -5.979
Val149 -2.776 -0.154 -2.931 Ser153 -2.241 -1.166 -3.407
Phe384 -1.855 -0.715 -2.570 Asp176 -1.749 -1.231 -2.981
Leu390 -2.337 0.322 -2.016 Phe384 -2.800 -0.040 -2.840
Met156 -1.810 0.237 -1.573 Phe388 -2.281 -0.547 -2.828
Asp176 0.241 -1.735 -1.494 Leu150 -2.355 -0.405 -2.761
Glu157 -1.093 -0.142 -1.236 Met156 -3.121 0.637 -2.484
Tyr392 -0.749 -0.133 -0.882 Trp361 -1.895 -0.210 -2.105
Ala173 -0.350 -0.518 -0.868 Val149 -1.895 0.161 -1.734
Trp172 -0.349 -0.486 -0.835 Gly391 -2.264 0.814 -1.450
and Phe3887.39 both creating pi stacking interactions with the other side of the lig-
and. The key residue for WB4101 (Phe3887.39) lies 3 A˚ away from the ligand, and
the less important residue is 3.5 A˚ away. The cavity analysis for this pose shows a
more than twofold contribution to the binding energy for Phe3887.39. This structure
and binding pose do agree with these mutation data, according to the cavity analy-
sis (Table 4.6). The prazosin docked structure shows a stronger interaction between
the ligand and Phe3847.34 than with Phe3887.39, also verifying the integrity of this
binding site. That these structures were obtained for the β2 template structure, for
which there is slightly higher sequence identity, rather than for the β1 template
supports the assertion that a template-target pair with higher sequence identity is
more likely to produce a high quality structure.
Yohimbine (Figure 4.8) is a potent α2 inverse agonist, often used as a bench-
mark ligand against which other ligand binding affinities are measured. Wang,
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Figure 4.8: Yohimbine, originally discovered for its aphrodesiac properties, is a potent and
selective α2 adrenergic inverse agonist.
et al. recently characterized the binding affinity of several agonists and antago-
nists with α2a and mutant receptors containing changes to TMs 2, 3, and 5.131 The
most striking effect came from the mutation of Asp1133.32 to asparagine, which
completely eliminated yohimbine binding but allowed a small amount of agonist
mediated activation. The next most important residues are in TM5, Ser2005.42 and
Ser2045.46. These had a greater effect on agonist binding, where they are expected
to form crucial interactions with the catechol hydroxides, but mutation to Alanine
resulted in a three- to four-fold decrease in yohimbine affinity. The least important
residues, Asp1303.49 and Asp792.50, are deeply buried in the TM core. The highly
conserved Asp3.49 is expected to be involved in the TM3-TM6 ionic lock control-
ling activation, and is too far away from other important residues for direct ligand
interaction. Similarly, Asp2.50 is positioned to interact with Asn1.50 and Asn7.49 to
form the stabilizing polar network seen in the bovine rhodopsin crystal structure.
An additional study shows a dramatic, 300-fold decrease in yohimbine binding
upon mutation of Phe4127.39, implying the upper section of TM7 is more likely to
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directly interact with the antagonist.132
Both the β1 and β2 templates yielded identical helix rotations for the α2a struc-
ture, so the differences in binding can be attributed to changes in the helix orienta-
tions due to the template. The best α2a-β1 docked structure by local cavity inter-
action (Figure 4.9) showed close interactions with Asp1133.32 (1.88 A˚ to the proto-
nated amine) and Ser2045.46 (1.86 A˚ to the hydroxide). Ser2005.42 was not observed
interacting with the ligand, but the residue is positioned such that it may inter-
act with the ester group in a dynamic environment. Most importantly, Phe4127.39
forms a pi stacking interaction with the indole rings and appears in the cavity anal-
ysis with a favorable -4.206 kcal/mol stabilization energy (Table 4.7). This docking
pose, even before further refinement with molecular dynamics, agrees well with
the published mutation data. This agreement is better than the corresponding best
docked α2a-β2 structure, which is consistent with the increased sequence identity
between target and template: α2a and β1 turkey share 46% TM sequence identity,
while α2a and β2 only share 39%.
This structure also shows Tyr3946.55 interacting directly with the indole nitro-
gen on the ligand (2.12 A˚). This residue, analagous to Asn6.55 in the β receptors
shown to be important for stereoselectivity, is a good candidate for further muta-
tion studies and may be important for adrenergic ligand selectivity.
The favored α2b rotations shift TMs 1, 2, 4, and 7 for the β2 template and TMs
4, 5, and 6 for the β1 template. While the α2b-β2 structure does form good protein-
ligand interactions with Asp923.32 (1.81 A˚ to the protonated amine) and an addi-
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Table 4.7: The key residue implicated by mutation studies, Phe4127.39, appears in the cav-
ity analysis for α2a-β1 docked with yohimbine. However, Asp1133.32 with a favorable
Coulomb energy of -2.423 kcal/mol does not show a favorable energy due to Van der
Waals repulsion after cavity optimization places the protonated amine very close to that
residue (1.88 A˚). Energies are reported in kcal/mol.
Residue VdW Coulomb Total
Tyr394 -1.381 -0.834 -4.591
Ser204 2.415 -2.415 -4.323
Phe412 -4.819 0.614 -4.206
Phe390 -3.122 0.153 -2.970
Leu110 -1.555 -0.456 -2.012
Cys201 -1.843 0.090 -1.753
Ser200 -1.371 -0.312 -1.683
Phe205 -1.853 0.183 -1.670
Lyn409 -1.408 -0.021 -1.429
Val197 -1.164 -0.113 -1.278
Figure 4.9: Yohimbine has less conformational flexibility than the antagonists docked for
the α1 and β receptors, so only one primary conformation was important for docking. The
docked ligand interacts with conserved residues on TMs 3 and 5, and in the α2a docked
structure is positioned close to Phe4127.39 implicated in mutation studies.
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tional unpredicted interaction with Glu732.65 (1.75 A˚ to the hydroxide), Phe4127.39
is rotated too far towards the lipid to allow the ligand to interact with the im-
plicated TM5 serines. This may indicate that this conserved phenylalanine is not
reponsible for a conserved interaction, but considering the lower sequence identity
between α2b and the available crystal structures, it is more likely that these rota-
tions are not correct for α2b. Both α2b-β1 and α2b-β2 have small rotations in TMs
5 and 7, respectively, that shift the important binding residues closer to the binding
site, and it is possible that a broader docking strategy involving a diverse ensemble
of low-energy TM bundles from the η rotation analysis may show a better binding
site for this system.
The final rotations favored for α2c are closer to the template crystal structures
than those for α1b: the recurring 15◦ anticlockwise rotation of TM4 appears for
the α2c-β2 structure, and TM6 is rotated 45◦ clockwise for α2c-β1. The primary
interaction in the binding cavity for the α2c-β1 structure involves Phe4237.39, a
cation-pi interaction with the protonated amine, but this functional group on the
ligand is expected to interact with the necessary Asp1313.32 instead. While this as-
partate does appear in the cavity analysis (Table 4.8), it contributes only a small
amount to the overall binding energy. There is no polar interaction with Ser2145.42
or Ser2185.46, though the O-methyl groups on the ligand are accessible to alter-
native rotamers of both residues. This structure could be refined to reflect the
mutation data more clearly, both with selective SCREAM rotamer scans and with
annealing dynamics. In addition, the α2c-β2 structure did not support a plausible
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Table 4.8: Both key residues involved in yohimbine binding, Phe4237.39 and Asp1313.32,
appear in the cavity analysis for α2c-β1 docked to yohimbine, but key TM5 serine residues
are conspicuously absent. Like many of the coarsely docked structures, this binding site
should improve with further refinement with binding site annealing or selective sidechain
optimization with SCREAM. Energies are reported in kcal/mol.
Residue VdW Coulomb Total
Phe423 -5.370 -0.001 -5.371
Tyr402 -3.336 -0.198 -3.571
Val132 -2.965 0.353 -2.612
Phe219 -2.977 0.407 -2.570
Trp395 -2.036 -0.394 -2.431
Leu128 -1.174 -0.733 -1.907
Cys215 -1.476 -0.319 -1.795
Cys135 -2.396 0.670 -1.726
Tyr427 -2.192 0.561 -1.631
Ile211 -0.914 -0.611 -1.525
Asp131 -0.448 -0.920 -1.368
yohimbine docked pose, indicating that the overall orientation of the β2 template
may be too different from the native α2c structure for a simple homology approach
to model.
4.4 Conclusion
In building homology models for the human adrenergic receptors based on avail-
able crystal data, sequence identity between the target receptor and the template
was a good but not perfect indicator of the model’s ultimate success. As this work
focused primarily on obtaining swift, coarse results for all eight uncrystallized hu-
man adrenergic receptors, many options remain for further structure optimization.
The OptHelix method for helix optimization provides another set of bundles for
each receptor-pair, and may result in more native-like helices. Replacement of
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charged residues in the TM caps as in Chapter 2 may reveal different low-energy
η rotations, especially for cases with lower sequence identity between target and
template where the orientation of the TM bundle is less likely to resemble the na-
tive structure. The SuperBiHelix method, which adds θ and φ to the η rotational
sampling of BiHelix, can fine-tune the template orientation of these low-identity
cases as well.
The subtype selective antagonist docking suggest a series of mutation studies
that may be performed both in silico and in the lab. In particular, the α1a antago-
nist interaction with the conserved Tyr1845.36 points towards a possible important
interaction for allosteric antagonists, allowing a ligand to engage TM5 without dis-
rupting residues closer to the intracellular side where activation takes place.
For the structures with plausible helix rotations but unsatisfactory docking, fur-
ther investigation into docking strategies will yield more plausible results. The
newly developed DarwinDock features a panoply of variations for both pose pre-
diction and final complex optimization that may be tuned to obtain a reasonable
structure, and alternate methods for choosing a binding site may be employed.
Recent studies of the adenosine A2A receptor in the Goddard group as well as mu-
tation studies for a variety of systems have shown that the extracellular loops play
a role in ligand binding, so complete validation of these systems will include fully
modeled loops.
Finally, with full predicted structures for all human adrenergic receptors, de-
tailed activation studies may be performed with full-solvent molecular dynamics.
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The comparison of systems with constitutive activity (like β2) with those that have
less (like the α1 receptors) may illuminate important processes for activation as
well as interactions that stabilize an inactive state. The structures predicted and
optimized here are antagonist-stabilized inactive structures, so attention should be
paid to interhelical interactions that anchor the TM helices into place, preventing
activation or ligand replacement by a diffusible agonist.
From ab initio structure prediction to nanosecond timescale MD through to a
complete set of 3D structures for the human adrenergic receptors, theory and ex-
periment influence and benefit from one another. The full structure of the turkey
β2 receptor was predicted using the amino acid sequence and validated with sta-
bilizing mutation data from experiment. The methods used for that prediction can
now be used with more confidence to predict the structures of systems with less
experimental data, and in turn provide further leads for experiment. The crys-
tal structure itself served as an experimental starting point for MD studies of the
activating protein, and offered insight into helix movements that initiate activa-
tion as well as possible mutations to stabilize an active receptor. Finally, both the
β2 and β1 crystal structures were built upon to create quick and useful models
of the closely related adrenergic subfamily of receptors. While some of the mod-
els require refinement, they do give some idea of residue positioning, binding site
similarities and differences among the different subtypes, and potential mutation
studies. With increasing confidence in theoretical methods ensured by validation,
theory can enable avenues of scientific exploration otherwise unavailable.
